Rebiopsy is highly recommended to identify the mechanism of acquired resistance to EGFR-TKIs in advanced lung cancer. Recent advances in multiplex genotyping based on circulating tumor DNA (ctDNA) provide a strong and non-invasive alternative for detection of the resistance mechanism. Here we report a multiple metastatic NSCLC patient who was detected to have pure EGFR 19 exon deletion (negative for EML4-ALK and ROS1 in both IHC-based and sequencing assay) in the primary lesion and responded to first-line and second-line EGFR-TKI treatments (erlotinib then HY-15772). At 8 months, most lesions remained well controlled except for the liver metastases which presented dramatic progression. Considering the high risk of bleeding in rebiopsy of hepatic lesions, we conducted a multiplex genomic profiling with ctDNA. Results reported coexistence of EGFR mutation and EML4-ALK gene translocation in plasma which heavily indicated that ALK was the primary reason for progression of the liver lesions. This deduction was supported by the repeated response to ALK inhibitors (crizotinib then AP26113) of the hepatic metastases. This is the first report of the existence of ALK rearrangement in metastatic lesions in an EGFR mutated patient. It highlighted the feasibility and advantages of using ctDNA multiplex genotyping in identifying the heterogeneity across lesions and the resistance mechanism of targeted treatments.
28 February 2023 in Journal of Cancer Research and Clinical Oncology
Objective: To evaluate the relationship between body fat index and pulmonary health. Methods: In the multiethnic population-based cross-sectional study, a multivariable linear regression model was adapted to assess the association of fat mass/percentage with forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC). The Mendelian Randomization (MR) method was used to assess the causal associations of fat mass/percentage in specific body parts with FEV1 and COPD risk. Sensitivity analysis of MR was performed to assess the robustness of estimates. Results: In the cross-sectional analysis, a non-linear relationship was observed between fat mass and FEV1 without adjustment. After multivariate adjustment, the negative associations of fat mass/percentage with FEV1/FVC were found. In the MR study, genetically determined fat presented a negative causal effect on FEV1 (e.g., estimate = − 0.170, P < 0.001 for left leg fat mass). The causal associations of genetically determined body fat with clinical diagnosis COPD were also determined (e.g., OR = 1.936, P < 0.001 per 1.9 kilograms increase in left leg fat mass). Conclusion: We present strong evidence on the causal relationship between body fat mass/percentage and both the deterioration of lung function and the increased risk of COPD. Additional efforts are required to mitigate the negative effects of body fat.
Early recovery after lung transplantation involves psychological distress, symptom burden, functional limitations, and recurrent readmissions. We examined whether anxiety and depressive symptom severity were differentially associated with graft-related and surgery-related recurrent readmissions during the first 6 months after transplantation. In this prospective single-center cohort, 74 adult lung transplant recipients completed assessments at 1, 3, and 6 months. Anxiety, depressive symptoms, health-related quality of life, and transplant-related symptoms were assessed using validated instruments. Readmissions were adjudicated by principal discharge diagnosis and analyzed as recurrent events using mean cumulative function curves and multivariable Poisson regression with follow-up time as an offset. At 6 months, mean cumulative readmission burden was 0.39 events per patient for graft-related readmissions and 0.26 for surgery-related readmissions. Anxiety severity grade was associated with graft-related readmission (incidence rate ratio [IRR], 1.63; 95% confidence interval [CI], 1.08-2.48), whereas depressive symptom severity was associated with surgery-related readmission (IRR, 2.81; 95% CI, 1.20-6.59). Physical Functioning improved from 22.5 to 72.5, whereas psychological recovery and symptom resolution were more gradual. During the first 6 months after lung transplantation, anxiety and depressive symptom severity were associated with different cause-specific recurrent readmission profiles. These interval-level associations indicate clinically relevant recovery vulnerability rather than temporal causation. Brief GAD-7 and PHQ-9 screening may add context to symptom assessment and clinical surveillance during early follow-up.